Diet Drugs Face FDA Scrutiny

A Food and Drug Administration report Tuesday citing safety issues with a proposed obesity drug sent shares of its manufacturer down 40%, the latest setback for a field that once looked like a big money-maker for the pharmaceutical industry.

The obesity drug lorcaserin from Arena Pharmaceuticals Inc. faces a tough battle when an FDA advisory...